Picture of Venture Life logo

VLG Venture Life News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

REG - Venture Life Group - Results of AGM

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST5172Pa&default-theme=true

RNS Number : 5172P  Venture Life Group PLC  20 June 2022

20 June 2022

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Results of AGM

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, held its
Annual General Meeting ("AGM") earlier today at the offices of Simmons &
Simmons LLP, CityPoint, 1 Ropemaker St, London EC2V 9HT.

Ordinary resolutions 1 to 5 were duly passed together with special resolution
7. Special resolution 6 was not passed. Proxy votes were received in respect
of approximately 68% of the Company's issued share capital and the final votes
received in respect of each resolution were as follows:

 Resolution                                                                      Number of votes for  % Votes for  Number of votes against  % Votes against  Number of votes withheld
 1.    To receive and adopt the reports of the Directors and auditor and the     84,876,146           99.41%       500,565                  0.59%            1,000
 audited accounts of the Company for the year ended 31 December 2021

 2.    To re-elect as a Director, Sharon Daly (nee Collins), who seeks           85,354,797           99.97%       21,513                   0.03%            1,401
 re-election
 3.    To appoint Daniel Wells as a Director of the Company                      85,354,797           99.97%       21,513                   0.03%            1,401
 4.    To appoint Paul McGreevy as Non-Executive Director and Chair of the       85,350,997           99.97%       25,313                   0.03%            1,401
 Company
 5.    The Directors are authorised to allot shares in the Company               63,554,349           74.44%       21,822,362               25.56%           1,000
 6.    The Directors are authorised to allot equity securities for cash          65,519,931           74.40%       21,856,780               25.60%           1,000
 7.    The Company is authorised to make one or more market purchases of         85,355,463           99.97%       22,248                   0.03%            -
 ordinary shares

For further information, please contact:

 

Venture Life Group PLC
 
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint
Broker)
                +44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong  (Corporate Finance)
 
+44 (0) 20 74963000

Jonathan Dighe (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal
infections and proctology, and dermo-cosmetics for addressing the signs of
ageing. Its products are sold in over 90 countries worldwide.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBKKBBNBKDCAB

Recent news on Venture Life

See all news